Pharmaceutical giant Lupin has secured final US FDA approval for its generic version of Pitolisant tablets, aimed at treating narcolepsy and excessive daytime sleepiness.
- Lupin receives US FDA approval for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.
- The generic is bioequivalent to Harmony Biosciences' branded drug, Wakix.
- Indicated for excessive daytime sleepiness (EDS) and cataplexy in patients aged 6 and older.
Indian pharmaceutical leader Lupin announced on Monday that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets. The approval covers two specific dosages: 4.45 mg and 17.8 mg.
The U.S. FDA has officially recognized Lupin's generic product as bioequivalent to Harmony Biosciences' proprietary drug, Wakix. This means the generic version provides the same therapeutic effect and safety profile as the branded medication, typically at a more competitive price point for the end consumer.
Why This Matters
BozokMedia analysis shows that this approval allows Lupin to penetrate a specialized segment of the neurology market. By offering a bioequivalent alternative to Wakix, Lupin is poised to capture a significant share of the narcolepsy treatment market in the United States, enhancing its revenue streams from the North American region.
"The entry of high-quality generics into the US market is critical for reducing the financial burden on patients with chronic neurological conditions."
Pitolisant is a prescription medicine specifically designed to treat excessive daytime sleepiness (EDS) or cataplexy in individuals 6 years of age and older who have been diagnosed with narcolepsy. Narcolepsy is a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of muscle weakness.
This approval comes at a time when Lupin is aggressively expanding its specialty pipeline. In a related move, the company recently acquired an 82.2% stake in Kaveri Therapeutics and licensed two oncology assets for $1.6 million, signaling a broader shift toward high-value specialty medicines.
| Feature | Wakix (Reference) | Lupin Generic |
|---|---|---|
| Active Ingredient | Pitolisant | Pitolisant |
| Indication | Narcolepsy/EDS | Narcolepsy/EDS |
| Price Point | Premium/Branded | Competitive/Generic |
Frequently Asked Questions
Q1: What is Pitolisant used for?
A: It is used to treat excessive daytime sleepiness and cataplexy in patients aged 6 and older with narcolepsy.
Q2: What does 'bioequivalent' mean in this context?
A: It means that Lupin's generic drug performs the same way in the body as the original branded drug, Wakix, ensuring identical efficacy.
